Skip to main content

Table 1 Patient and tumor characteristics

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

   Total group (n = 94) Study group (n = 18) Control group (n = 18) p-values*
   n % value (range) n % value (range) n % value (range)  
  Age < 60 years 36 38.3   13 72.2   5 27.8   
  Age ≥ 60 years 58 61.7   5 27.8   13 72.2   
  Age at onset of recurrence disease (years)    62.0 (53–71)    48.0 (45–68)    66.5 (57–73) (0.006)
  Time to first recurrence < 3 months 10 10.3   9 50.0   0 0   
  Time to first recurrence ≥ 3 months 81 83.5   6 33.3   18 100   
  Previous recurrence free survival (months)    24.0 (10–73)    2.3 (2–8)    38.1 (18–99) (0.003)
  First recurrence 49 52.1   9 50.0   7 38.9   
  Several recurrences 45 47.9   9 50.0   11 61.1   
Previous treatment Operation 72 76.6   12 66.7   13 72.2   (0.177)
  Chemotherapy 25 26.1   6 33.1   8 44.0   (0.978)
  Radiotherapy 63 67.0   15 83.3   17 94.4   (0.584)
  Previous total radiation dose (Gy)    64.2 (33–105)    68.1 (50–105)    66.2 (59–77) (0.696)
rTNM-stage T1-T2 38 40.4   5 27.8   7 38.9   (0.812)
  T3-T4 45 47.9   10 55.6   9 50.0   
  Tx 9 9.6   3 16.7   2 11.1   
  N0 67 71.3   13 72.2   12 66.7   (1.000)
  N1-N2 21 22.4   3 16.7   4 22.2   
  N3 3 3.2   2 11.1   1 5.6   
UICC-stage Stage I-II 31 33.0   6 33.3   5 27.8   (1.000)
  Stage III-IV 63 67.0   12 66.7   13 72.2   
Histology SCC 75 79.8   17 94.4   15 83.3   (0.735)
  Other 19 20.2   1 5.6   3 16.7   
Grading Low Grade (G1-G2) 50 53.2   12 66.7   7 38.9   (0.156)
  High Grade (G3-G4) 41 43.6   6 33.3   11 61.1   
Localization Oral cavity 24 25.5   7 38.9   4 22.2   (0.308)
  Oro-, nasopharynx 26 27.7   5 27.8   9 50.0   
  Hypopharynx, larynx 6 6.4   2 11.1   1 5.6   
  Lymph node 8 8.5   3 16.7   2 11.1   
  Other 30 31.9   1 5.6   2 11.1   
Resection margins R0 37 39.4   4 22.2   6 33.3   (0.766)
  R1 32 34.0   10 55.6   5 27.8   
  R2 11 11.7   3 16.7   4 22.2   
  Rx (unsure) 6 6.4   1 5.6   - -   
  No debulking 8 8.5   1 5.6   3 16.7   
Tissue invasion L0, V0, Pn0 26 27.7   3 16.7   2 11.1   (0.733)
  L1, V1 or Pn1 20 21.3   5 27.8   7 38.9   
  No neck dissection 48 51.1   10 55.6   9 50,0   (1.000)
  1. Shows the patient and tumor characteristics for the total group, study group receiving the cetuximab-taxane schema and the matched pair control group that potentially influence prognosis. Differences between the study group and the control group were analyzed by *chi-square test and Mann–Whitney U test